Annual report pursuant to Section 13 and 15(d)

Reverse Merger (Tables)

v3.8.0.1
Reverse Merger (Tables) - OncoGenex Pharmaceuticals, Inc [Member]
 12 Months Ended
Dec. 31, 2017
Business Acquisition [Line Items]  
Summary of Final Purchase Price

The final purchase price is summarized as follows (dollars in thousands, except per share amounts):

 

Shares of the combined company to be owned by OncoGenex equity holders

 

 

2,736,709

 

Multiplied by the price per share of OncoGenex stock

 

$

4.62

 

Value of shares of the combined company owned by OncoGenex equity holders

 

$

12,643

 

Fair value of options and warrants assumed

 

$

207

 

Fair value of contingent value rights assumed

 

$

200

 

Total purchase price

 

$

13,050

 

 
Summary of Final Purchase Price Allocation

The final purchase price allocation is as follows (in thousands):

Cash, cash equivalents and marketable securities

 

$

12,376

 

Prepaid expenses and other assets

 

 

518

 

Intangible assets license agreements

 

 

8,610

 

Accounts payable, accrued expenses and other liabilities

 

 

(4,054

)

Deferred tax liability

 

 

(2,928

)

Contingent value rights

 

 

(200

)

Excess negative goodwill

 

 

(1,272

)

Total purchase price

 

 

13,050

 

 
Summary of Pro Forma Results of Operation

 

 

For the year ended

 

 

For the year ended

 

 

 

December 31,

 

 

December 31,

 

 

 

2017

 

 

2016

 

 

 

(Unaudited)

 

 

(Unaudited)

 

Revenue

 

$

—

 

 

$

5,062

 

Net loss applicable to common shareholders

 

$

(20,111

)

 

$

(21,363

)

Net loss per share-basic and diluted

 

$

(4.19

)

 

$

(7.79

)

Weighted average shares

 

 

4,794,421

 

 

 

2,743,906